Intellia Therapeutics (NTLA) Common Equity (2015 - 2026)
Intellia Therapeutics (NTLA) posted quarterly Common Equity of $620.9 million for Q1 2026, down 20.38% year-over-year from $779.9 million in Q1 2025, and down 7.51% quarter-over-quarter from $671.4 million in Q4 2025.
Intellia Therapeutics (NTLA) Common Equity (2015 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has reported Common Equity for 12 consecutive years, with $620.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 20.38% year-over-year to $620.9 million; the TTM figure through Mar 2026 stood at $620.9 million (down 20.38% YoY), while the FY2025 annual figure was $671.4 million, down 23.0% from the prior year.
- Common Equity eased to $620.9 million in Q1 2026 per NTLA's latest filing, from $671.4 million in the prior quarter.
- Across five years, Common Equity topped out at $1.2 billion in Q4 2022 and bottomed at $620.9 million in Q1 2026.
- Historically, Common Equity has averaged $920.9 million across 5 years, with a median of $953.8 million in 2022.
- Annual changes were most pronounced in 2022 — Common Equity surged 77.96% — and 2025, when it retreated 26.34%.
- Intellia Therapeutics' Common Equity stood at $1.2 billion in 2022, then fell by 15.01% to $1.1 billion in 2023, then dropped by 16.97% to $872.0 million in 2024, then decreased by 23.0% to $671.4 million in 2025, then declined by 7.51% to $620.9 million in 2026.
- Business Quant data shows NTLA's Common Equity at $620.9 million in Q1 2026, $671.4 million in Q4 2025, and $748.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Intellia Therapeutics | 1.67 Bn | 1.67 Bn | - | 727.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 727.71 Mn |
| Mar 31, 2026 | 620.94 Mn |
| Dec 31, 2025 | 671.39 Mn |
| Sep 30, 2025 | 748.42 Mn |
| Jun 30, 2025 | 715.26 Mn |
| Mar 31, 2025 | 779.92 Mn |
| Dec 31, 2024 | 871.96 Mn |
| Sep 30, 2024 | 962.62 Mn |
| Jun 30, 2024 | 971.06 Mn |
| Mar 31, 2024 | 1.04 Bn |
| Dec 31, 2023 | 1.05 Bn |
| Sep 30, 2023 | 1.04 Bn |
| Jun 30, 2023 | 1.10 Bn |
| Mar 31, 2023 | 1.19 Bn |
| Dec 31, 2022 | 1.24 Bn |
| Sep 30, 2022 | 824.95 Mn |
| Jun 30, 2022 | 880.55 Mn |
| Mar 31, 2022 | 953.75 Mn |
| Dec 31, 2021 | 1.04 Bn |
| Sep 30, 2021 | 1.11 Bn |